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Abstract
Background: Smoking in pregnancy remains a public health challenge. Nicotine replacement
therapy (NRT) is effective for smoking cessation in non-pregnant people, but because women
metabolise nicotine and cotinine much faster in pregnancy, it is unclear whether this will be
effective for smoking cessation in pregnancy. The NHS Health Technology Assessment Programme
(HTA)-funded smoking, nicotine and pregnancy (SNAP) trial will investigate whether or not
nicotine replacement therapy (NRT) is effective, cost-effective and safe when used for smoking
cessation by pregnant women.
Methods/Design: Over two years, in 5 trial centres, 1050 pregnant women who are between 12
and 24 weeks pregnant will be randomised as they attend hospital for ante-natal ultrasound scans.
Women will receive either nicotine or placebo transdermal patches with behavioural support. The
primary outcome measure is biochemically-validated, self-reported, prolonged and total abstinence
from smoking between a quit date (defined before randomisation and set within two weeks of this)
and delivery. At six months after childbirth self-reported maternal smoking status will be
ascertained and two years after childbirth, self-reported maternal smoking status and the
behaviour, cognitive development and respiratory symptoms of children born in the trial will be
compared in both groups.
Discussion: This trial is designed to ascertain whether or not standard doses of NRT (as
transdermal patches) are effective and safe when used for smoking cessation during pregnancy.
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Maternal smoking during pregnancy harms unborn chil-
dren and, as up to 30% of pregnant women smoke [1], it
is a significant public health problem. The adverse effects
of smoking during pregnancy include an increased risk of
miscarriage and stillbirth, accounting for 4000 deaths
annually, and of pre-term birth and low birth weight lead-
ing to increased perinatal morbidity [2,3]. Children of
mothers who smoke whilst pregnant are at increased risk
of neo-natal mortality, sudden infant death syndrome
and asthma [2]. Maternal smoking whilst pregnant is also
associated with an increased risk of attention deficit and
learning problems in childhood [3,4]. Currently only
around 25% of pregnant smokers stop for even part of
their pregnancy and, of these, around two thirds re-start
post-natally [1].
Effective methods for promoting smoking cessation by
pregnant women are required. The most effective smoking
cessation therapy in non-pregnant smokers is a combina-
tion of behavioural support and pharmacotherapy with
either nicotine replacement therapy (NRT) [5] or bupro-
pion [6]. Behavioural support alone can increase smoking
cessation rates by up to 7% [7] and the addition of phar-
macotherapy increases this further by 1.5 to 2-fold. Behav-
ioural support is usually provided without
pharmacotherapy, however, because of concerns that drug
therapy may harm the fetus [8]. This is understandable for
bupropion, but is far less logical for nicotine.
Pregnant women who smoke will already expose their
unborn children to nicotine. Nicotine has well docu-
mented potential adverse effects in pregnancy, since it is a
vasoconstrictor and nicotine from cigarettes causes dose-
related increases in maternal blood pressure and heart rate
and has lesser effects on the fetal heart rate [9]. In rats
chronic nicotine exposure is associated with dose-depend-
ant alterations in behavioural and cognitive responses,
CNS toxicity and a diminished adrenal response to
hypoxia that, in humans, could pre-dispose to sudden
infant death syndrome [9]. Consequently, nicotine may
also be responsible for the attention deficit and learning
problems that are described above [4]. Cigarette smoke,
however, contains numerous other toxins in addition to
nicotine and it is not known which of these actually cause
harm, though the fetal effects of nicotine have been most
widely studied. The cardiovascular effects of nicotine from
NRT are less than those observed from smoking and regu-
lar NRT use generates lower plasma nicotine concentra-
tions (when body weight is accounted for) than those in
the animal experiments described above [9]. There is also
no evidence that NRT use in pregnancy results in higher
plasma nicotine concentrations than smoking [9]. For
these reasons, and because using NRT in pregnancy results
in exposure to only nicotine and no other toxins, there is
expert consensus that NRT use is safer than smoking in
pregnancy as long as pregnant women using NRT do not
receive more nicotine from NRT than they would have
done by smoking [10,11]. It is difficult, though, for health
professionals to give clear guidance to pregnant women
on using NRT when the safety of NRT in pregnancy is jus-
tified primarily on theoretical grounds and its efficacy has
not been established.
To date, evidence on the effectiveness of NRT in preg-
nancy comes from 3 studies and is inconclusive [12-14].
Two of these studies were trials investigating NRT as
transdermal patches. [12,13]. but one [13] was stopped
after only 40 patients had been randomised. The other
[12], however, randomised 250 women but produced no
clear evidence that NRT was effective, since the odds ratio
for smoking cessation using NRT versus placebo was 1.1
with a 95% CI of 0.7 to 1.8. This odds ratio is much lower
than that obtained from meta-analysis of trials of NRT
patches in non-pregnant subjects (OR, 1.74) [5] and raises
questions about whether using NRT in pregnancy is effec-
tive for smoking cessation. The third study was not pla-
cebo controlled and randomised women to intensive
behavioural support with an additional option to use NRT
patches and/or gum).)[14] or a 'normal care' group which
received only very minimal smoking cessation advice.
Although, 75 women in this trial opted to use NRT, this
design makes it difficult to disentangle any effect of NRT
from that of intensive behavioural support. Where
reported, no harmful effects of NRT were demonstrated in
these 3 studies. In the larger patch trial [12], babies born
in the NRT group were significantly heavier than others
[mean birth weight (adjusted for prematurity) difference
= 186 g (95%CI 35,336 g)], suggesting that pure nicotine
as NRT has less impact on fetal growth in utero than
smoking. Additionally, in the trial which allowed a group
of women to use either NRT patches or gum or a combi-
nation of these, mean birth weights in fetuses born after
37 weeks were not statistically different between the 2 trial
groups [non-significantly lighter (by 32 g) in NRT group].
In both trials that reported the distribution of low birth
weight infants between groups [12,14], no significant dif-
ferences were noted.
It has recently become apparent that conventional doses
of nicotine contained in NRT may be insufficient for preg-
nant women and this may explain the negative findings
from the one trial of NRT in pregnancy. In pregnancy, the
metabolic clearances of nicotine and cotinine (the princi-
pal metabolite of nicotine) are increased by 60% and
140% respectively. [15]. Accordingly, even when pregnant
women take standard doses of NRT for adequate periods,
these may still be ineffective because they may require
higher doses of NRT to replace the nicotine they would
have received via smoking. Higher doses of NRT might,Page 2 of 15
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very little human-subject research into the effects of nico-
tine on the developing fetus, it is not known whether
these might increase the risk of fetal damage. Until the
effectiveness of the current conventional dose of NRT is
established, it is hard to justify trials of higher ones.
In summary, although consensus opinion suggests that
taking NRT during pregnancy is likely to be safer than
smoking [8,10,11,16], there is little direct trial evidence to
support this and we do not know if NRT is actually effec-
tive in promoting smoking cessation amongst pregnant
smokers. The SNAP trial will produce direct evidence on
these important questions and will investigate whether or
not NRT is more effective than placebo in achieving smok-
ing cessation for women who and are between 12 and 24
weeks pregnant, who currently smoke 5 or more cigarettes
daily and who smoked 10 or more cigarettes daily before
pregnancy.
Methods/Design
Ethical approval to conduct this study from the Oxford-
shire REC A ethics committee (ID number 04/Q1604/85)
Treatment group
Pregnant women will receive an eight week course of 15
mg/16 hr NRT transdermal patches. Although many stud-
ies have used longer courses, there is no evidence that
these are more effective [5]. Patches will be issued in con-
junction with individual behavioural support (Section 10)
which is an effective smoking cessation intervention in
pregnancy [7]. Four weeks after their quit dates, women
who are not smoking will be issued with a second four
week supply of patches.
Control group
Women in the control arm of the trial will receive an iden-
tical placebo NRT patch and the same behavioural sup-
port as those in the treatment group. In both control and
intervention groups, participants will be blind to their
group allocation.
Randomised procedure
After collecting pre-randomisation baseline data, exhaled
carbon monoxide readings will be taken from women and
assuming that readings indicate that women do smoke
[cut off 8 ppm [17]], informed consent for trial entry will
be sought. After consenting to trial entry, women will
receive an initial behavioural support session before being
randomised. Full details are given later.
Randomisation will be via the Nottingham Trials Unit
web-based database and randomisation service. In each
centre the recruiting research midwife (RM) will have a
username and password. (S)he will log on to the trial web-
site that hosts the trial database, confirm that the patient
eligibility criteria are all met and enter an agreed mini-
mum amount of registration data about the participant
and centre before randomisation is possible. Data to be
entered at this stage are described later. The computer will
then issue a trial number which will be the unique identi-
fier for the trial participant and a trial pack number which
will reflect the treatment allocated. Randomisation will be
stratified by trial centre only.
Numbered packs of active and placebo patches will be dis-
tributed by Queens Medical Centre pharmacy and stored
in all participating ante-natal/ultrasound clinics. After
randomisation, the research midwife will select the patch
pack with the appropriate number and issue this to the
participant. The research midwife and the trial participant
will both be blind to group allocation. The research mid-
wife will issue NRT/placebo under the supervision of a
senior, local doctor via a patient group directive (PGD)
[18]. When research midwives visit women at home to
enrol them into the trial, immediate internet randomisa-
tion will not be possible. In this circumstance the research
midwife will return to her/his hospital base to randomise
the enrolled woman and the appropriate trial pack will be
posted to the trial participant.
Outcome measures
These relate to smoking, fetal loss, fetal and maternal mor-
bidity and health economic outcomes.
Primary end point: Self-reported, prolonged and total
abstinence [19] from smoking or the use of any non-phar-
macological nicotine containing substances between a
quit date set within two weeks of randomisation and
immediately prior to childbirth.
Prolonged abstinence cannot be comprehensively vali-
dated, but if participants report prolonged abstinence and
are abstinent at both time points below, they will be con-
sidered tohave a positive primary outcome. This is one
outcome requiring three different measures to be
achieved.
i) Self reported smoking cessation for at least 24 hours
before follow up at one month after quit date, validated by
exhaled CO measurement [cut off 8 ppm [17]].
ii) Self reported smoking cessation for at least 24 hours
before hospital admission for childbirth, validated by
exhaled CO measurement [cut off 8 ppm [17]].
Secondary end points:Page 3 of 15
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1. Self reported, prolonged abstinence [19] from smoking
between quit date and one month.
2. Self reported, prolonged abstinence [19] from smoking
between quit date and 6 months after delivery.
3. Self reported smoking cessation for previous 7 day
period at 6 months after delivery (point prevalence) [19].
4. Self reported, prolonged abstinence [19] from smoking
between quit date and 2 years after delivery.
5. Self reported smoking cessation for previous 7 day
period at 2 years after delivery (point prevalence) [19].
b) Fetal loss and morbidity
1. Fetal death and stillbirth
2. Neonatal death (i.e. from birth to 28 days)
3. Post-neonatal death (29 days to 2 years)
4. Individualized birth weight Z score (i.e. birth weight
adjust for gestational age, maternal height, maternal
weight at booking and ethnic group).
5. Apgar score
6. Cord blood ph
7. Gestational age at birth
8. Intraventricular haemorrhage
9. Neonatal enterocolitis
10. Neonatal convulsions
11. Congenital abnormality
c) Maternal morbidity and mortality
1. Maternal mortality
2. Mode of delivery
3. Proteinuria
4. Hypertension in pregnancy
d) Early childhood outcomes
1. Behaviour and development at 2 years
2. Disability at 2 years
3. Respiratory symptoms at 2 years
e) Health economic data
1. Duration of maternal hospital admission for childbirth
2. Duration of any admission (of baby) to special care
3. Health status at 6 months (EQ5D) [20]
Sample size
We need to recruit 525 women into each arm of the study.
A trial with 500 women in each arm would detect an abso-
lute difference of 9% in smoking cessation rates between
the two groups immediately before childbirth with a two-
sided significance level of 5% and a power of 93%. We
anticipate that up to 5% of women will be lost to follow
up and inflate our sample size (of 500) by a factor of 1.05
to allow for this. This size of study would allow us to
detect smaller treatment effects with lower power. For
example, we would have 80% power to detect an absolute
difference in cessation rates of 7%.
A Cochrane review has shown that approximately 10% of
women who are still smoking at the time of their first
antenatal visit will stop smoking with usual care and a fur-
ther 6% to 7% will stop as a result of a formal smoking
cessation program using intensive behavioural counsel-
ling [15]. This means that in our control group (placebo
plus intensive behavioural counselling) we can expect a smok-
ing cessation rate of around 16%. The most recent
Cochrane review of NRT, reports a treatment effect (odds
ratio) for transdermal patches of 1.74 95%CI (1.57–1.93)
[5]. Consequently, if we were to find NRT as effective in
pregnancy as it is generally, we could expect a smoking
cessation rate of approximately 25% in our treatment
group (NRT plus intensive behavioural counselling).
Inclusion criteria
Eligible women are women between 12 and 24 weeks
pregnant, who report smoking at least ten cigarettes daily
before pregnancy and who still currently smoke at least five
cigarettes daily. They also must have an exhaled CO read-
ing at least 8 ppm. Women may only enrol into the trial
once and may participate in other non-conflicting
research projects.
Exclusion criteria
Women with the following contraindications to the use of
NRT will be excluded: severe cardiovascular disease,
unstable angina, cardiac arrhythmias, recent cerebrovas-
cular accident or TIA, chronic generalized skin disorders
or known sensitivity to nicotine patches, chemical
dependence/alcohol addiction problems. Also, women
who cannot give informed consent and those with knownPage 4 of 15
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exclusion criterion.
Recruitment (see Figure 1)
All pregnant women between 12 and 24 weeks into preg-
nancy who smoke and are interested in stopping smoking
are potentially recruits to the study. Brief information
about the trial and patient information sheets (PIS) will,
therefore, be posted to all women who attend trial site
hospitals for ante natal care with their routine antenatal
ultrasound scan appointment letters (scans are usually
performed at between 12 and 20 weeks gestation). In each
trial hospital, a w.t.e. research midwife (RM) working
with non-w.t.e. clerical assistant will use a systematic
method to identify smokers who are interested in partici-
pating from all women attending for ultrasound examina-
tions. During piloting a questionnaire was used for this
and a similar instrument could be used in any or all of the
5 trial centres. The final method of identifying eligible
patients will be agreed with the Chief Investigator.
Research midwives will also agree a method for monitor-
ing the numbers of women identified as potentially eligi-
ble to join the trial and the proportion of these that
eventually enrol.
Consent
Women who are interested in participation will be asked
to discuss this with the research midwife. The research
midwife will ascertain if women are eligible to join the
study and have read the PIS at least 24 hours earlier. If
they have read the PIS, the research midwife will answer
any questions that women have about trial enrolment and
seek informed consent to:
i) trial participation
ii) collection of follow up data on materno-fetal outcomes
from medical records
iii) participants' registration with the Office for National
Statistics
iv) collection of a blood sample for cotinine estimation
and DNA extraction & storage
v) collection of saliva samples for cotinine estimation
vi) potential future contact for follow up studies by Uni-
versity of Nottingham based investigators
If women have not read the PIS, but express an interest in
the study, they will be given a copy and contacted after 24
hrs to determine whether or not they consent to enter the
trial. These women will be contacted after 24 hrs and if
they are still interested in enrolling in the study, informed
consent will be sought.
Once consent is recorded, baseline data, saliva, blood
samples and exhaled CO readings are obtained. Next the
research midwife delivers the first session of behavioural
support to the participant during which a quit date which
is within 2 weeks when they will start using transdermal
patches is agreed.
Registration & randomisation
Immediately after the behavioural support session, the
research midwife uses a PIN to log on to the University of
Nottingham internet randomisation service and enters the
mandatory enrolment data below, without which ran-
domisation will not be permitted. The participant is auto-
matically allocated a trial number (i.e. unique ID) and a
trial treatment pack number which identifies the treat-
ment required and the RM issues the corresponding trial
treatment pack.
It is anticipated that around 50% of trial participants will
need a home visit for intensive behavioral counseling and
subsequent randomization. In this situation, the research
midwife (RM) will ensure that all base line data including
the mandatory enrolment data is collected whilst visiting
the participant. The RM will return to base and randomi-
zation the participant via the internet before posting an
appropriate treatment pack to the study participant.
The research midwife then sends letters to the partici-
pant's general practitioner and hospital obstetrician to
inform them that she is enrolled in the trial. One copy of
the consent form is placed in the hospital medical records,
another accompanies the letter to the GP and the third is
sent to the Trial Office.
Further behavioural support
The research midwife will give the participant contact
details for the local NHS stop smoking service and also
pass the participants' details to this service. Participants
will receive up to 5 further behavioural support sessions
from the NHS stop smoking service according to an
agreed format.
Data handling
RMs will enter the data which they collect on to a secure
database hosted by the University of Nottingham via an
internet connection and will also make paper copies of
data collection to allow audit. Once data collection at any
one time point (e.g. baseline or one month) is complete,
the research midwife will photocopy the data collection
sheet and post a copy to the Trial Office. Infant records
within the database will be created from within maternalPage 5 of 15
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Flow of trial participants from recruitment to deliveryigure 1
Flow of trial participants from recruitment to delivery. Research midwives in each centre are responsible for accurate 
data entry to internet hosted database, for sending blood samples to appropriate university departments and accurate paper 
copies of data collection sheets from i) baseline (pre-randomisation) ii) one month follow up and iii) delivery to the Notting-
ham Trial Co-ordinating Team.
Prior to delivery, during hospital admission for delivery – data 
collected directly from trial participant to ascertain trial primary outcome.
RM collects data, including biochemical verification of smoking cessation 
status.  If RM not available, delivery suite staff collect data.  If women 
missed prior to delivery, RM collects data within 2 weeks of birth, if 
necessary, visiting the homes of women who report smoking cessation to 
One month follow up: Women return to RM for further treatment between 
3 and 6 weeks after randomisation. Women who are not smoking, confirmed 
by exhaled CO given one month’s further patch supply (double blind). Non-
returners sent postal questionnaire by NTCT to obtain data.  RM conducts 
CO validation for women who don’t return at 1 month, but report smoking 
cessation (home visit if necessary). 
During attendance for U/S dating scan, after consenting - women 
receive first session of behavioural support. Baseline pre-randomisation 
data and samples collected. Women set a quit date within 2 weeks of this 
session and agree to stop smoking from this date.   
Women who do not 
consent leave at any point 
of process
Up to 5 further sessions 
of behavioural support 
delivered by staff from 
NHS stop smoking 
services
delivered within 8 
weeks of randomisation
Randomisation: (during attendance for U/S dating scan, after 1st
behavioural support session). Mandatory, enrolment data entered into 
internet randomisation system.  RM is now allowed to randomise woman to 
intervention or control group.  4 weeks treatment (active or placebo 
transdermal patches) dispensed by RM with double blinding.  Contact details 
of randomised women passed to NHS stop smoking service & trial 
participants given contact details for this service.  
Before attendance for U/S dating scan - all women due to attend sent 
trial patient information sheet  
During attendance for U/S dating scan - RM identifies eligible women 
and seeks their consent for trial enrolment. 
Exclusions
Further data collection prior to discharge from hospital, after 
delivery. RM collects data from maternal or infant medical records before 
their discharge from hospital.  
BMC Health Services Research 2007, 7:2 http://www.biomedcentral.com/1472-6963/7/2ones and will automatically be linked to maternal and sib-
ling trial records.
Biological samples
i) For DNA extraction, 2 × 5 ml EDTA blood samples are
required. These can be refrigerated or frozen (if later than
24 hrs elapses between collection and dispatch). If frozen,
this needs to be to -20° centigrade. Samples will be dis-
patched to Professor Ian Hall at the University of Notting-
ham for long term archiving. Frozen samples require non-
glass tubes.
ii) Blood for serum cotinine estimation (5 ml sample
minimum) need to be placed in BD Gold top tubes (or
equivalent). These need to be frozen as per i) above before
transport to the Nottingham Trial Coordination Team
prior to dispatch to Professor Michael McCoughtrie at the
University of Dundee.
iii) Saliva for salivary cotinine estimation is also trans-
ported to Dundee after collection.
All frozen samples need to be transported on ice in non-
glass containers labelled with:
• Trial number
• Hospital number
• Subject's initials
Withdrawal from patch treatment
If for any reason, a participant terminates patch treatment,
every effort must still be made to collect follow up data.
Follow-up at one month after agreed quit date
Participants will return to the research midwife (RM) for
further supplies of patches. To allow some flexibility this
follow up will occur between 3 and 6 weeks after ran-
domisation. The RM will ascertain women's smoking sta-
tus and those who report not smoking regularly
(confirmed by exhaled CO measurement) will be issued
with a new trial treatment pack number (obtained by the
RM from the online database) and will receive a corre-
sponding treatment pack (containing 4 weeks' patches). A
saliva sample to measure cotinine levels on treatment will
be taken. The Trial Office will send a postal questionnaire
asking about smoking status to women who do not return
at one month. One postal and telephone reminder will be
used. When women report continued smoking cessation
and do not attend for further NRT, the research midwife
will contact them to arrange CO validation of this, visiting
them at home, if necessary.
Follow-up immediately before childbirth
When participants are admitted to hospital whilst in
established labour prior to childbirth, Delivery Suite staff
will contact the research midwife who will visit partici-
pants to ascertain their self-reported smoking status and
use of transdermal patches. Women who report absti-
nence from smoking in the previous 24 hours will be
asked by the research midwife to perform exhaled CO test-
ing and provide a saliva sample for cotinine estimation.
The RM will have overall responsibility for data collection
and will arrange with Delivery Suite staff for this to be
obtained in her/his absence. The RM will telephone those
missed whilst in hospital as soon as possible afterwards
(within 2 weeks maximum) to collect smoking behaviour
data. Where participants report smoking cessation, the
research midwife will measure their exhaled CO readings
and obtain a saliva sample for cotinine estimation, visit-
ing women at home if necessary.
Further infant, fetal and maternal data will be obtained
from medical records (details below)
Data monitoring by RM between data collection points
These data are required to ensure that the Data Monitor-
ing and Ethics Committee is provided with adequate
information to form an opinion concerning trial safety:
Development of major fetal abnormality between randomisa-
tion and labour onset
Fetal death between randomisation and labour onset
Maternal death between randomisation and labour onset
Hospital admission
Each month the Trial Office will provide RMs in the 5 cen-
tres with a list of trial numbers for participants who are
still pregnant. The RM will use these to access subjects'
computer records to obtain the information listed above.
In the event of a hospital admission the RM will assess
whether or not a serious adverse event has occurred and
act accordingly see below. If the RM enters a fetal death
into the database, this will automatically prevent further
infant follow up and the RM will liase with the mothers'
obstetrician to determine whether or not asking for follow
up information concerning smoking behaviour around
the anticipated time of delivery is acceptable. Major fetal
abnormalities will also be reported to the trial office who
will review these individually before deciding whether or
not the participant should be allowed to continue within
the trial.Page 7 of 15
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The Trial Office will "flag" participants (women and
babies) with the Office for National Statistics (ONS) at
birth to facilitate follow up. Each week during the 2 year
follow up period, the ONS will inform the trial team of
any post-neonatal (i.e. between 29 days and 2 years) or
maternal deaths.
Procedure for administering postal follow up 
questionnaires
(see Figure 2): After infant deaths, questionnaires will not
be sent and, where maternal deaths are reported, infants'
general practitioners will be consulted about the appro-
priateness of continued follow up. The Trial Office will
send questionnaires directly to study participants using
contact details provided at study recruitment. For non-
respondents or where questionnaires are returned
labelled "not at this address", the office will check partici-
pants' addresses by contacting infants' grandparents and,
if necessary, the ONS. ONS will trace the infant or mother
and provide details of the Primary Care Trust (PCT) which
provides their NHS health services and the Trial Office
will then contact the infant's general practitioner so that a
questionnaire can be sent. To maintain contact between
researchers and participants, study infants will be sent
Christmas cards and first birthday cards.
Follow-up 6 months after childbirth
A postal questionnaire, with one postal and one tele-
phone reminder, will be used to collect the data items
specified below.
Follow-up 1 year after childbirth
Two weeks before infants' 1st birthdays, parents will be
sent a questionnaire to collect the data items specified
below. Two weeks later, all participating infants will be
sent a 1st birthday card with a questionnaire reminder for
non-respondents.
Follow-up 2 years after childbirth
i) Parent questionnaire: Two weeks before infants' 2nd birth-
days, we will dispatch to parents a questionnaire to meas-
ure child behaviour, development, hospital admissions,
respiratory symptoms and maternal smoking behaviour.
Two weeks later, all participating infants will be sent a 2nd
birthday card with a questionnaire reminder for non-
respondents. The instrument uses standard questions to
record parents' reports of infants' respiratory symptoms
[21] and behaviour [22], developed from those used in
the MRC-funded UK Oscillation Study [23], with refer-
ence to the evidence base for questionnaire design [24].
ii) Health professional questionnaire: At the same time as
parents' questionnaires are dispatched, we will post par-
ticipants' general practitioners (GPs) a health professional
questionnaire (HPQ) to measure children's disability
according to a standard definition. [25] This brief instru-
ment is designed to be completed using medical records.
Health professionals completing these questionnaires
require relatively little knowledge of the patient and GPs
will be asked to complete them. If GPs cannot complete
HPQs, they will be asked to forward these to children's'
health visitors (HV). We will use an initial postal and sub-
sequent telephone reminder to GPs to obtain the required
information. The HPQ questionnaire has been validated
and used with GPs and HVs previously [26,27] and
requests data that HVs collect during their routine clinical
practice to provide external validation of parents'.
Data collection
Here the specific items of data to be collected at different
points during the trial are outlined.
a) Baseline (i.e. pre-randomisation) data collection
Although online forms will allow data to be inputted to
an online database, a paper copy of data will be kept for
audit purposes.
i) Mandatory enrolment data (i.e. required for randomisation)
The RM will collect the following data from participants
immediately after obtaining informed consent. The RM
must enter the following data items about participants to
the online database before randomisation is permitted:
DoB (valid range equiv to age 14–50)
participant's initials
hospital number
daily number of cigarettes smoked before pregnancy[28]
daily number of cigarettes smoked currently[28]
agreed gestational age at time of randomisation (valid range
120–246) [estimated delivery date will be calculated auto-
matically within database]
time elapsed since last cigarette
exhaled CO reading of at last 8 ppm
blood sample requested (for cotinine assay, DNA extraction
& storage)
indication that patient has signed consent form
indication that participant's contact details have been recorded
on paper (see below)Page 8 of 15
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All questionnaires & cards sent by SNAP Trial Office 
 
 
 
 
 
 
 
6 months (infant age): Postal questionnaire 
measuring self reported smoking status and 
health economic data. One postal / one 
telephone reminder. 
2 weeks before 1st birthday: postal 
questionnaire to mother Birthday card 
2 weeks before 2nd birthday: (infant age): 
Postal questionnaire to parents.  
Two years: (infant age): Postal questionnaire 
to GP / health visitor.  
Two years: All infants sent 2nd birthday card 
 
Non-respondents to questionnaire above: One 
postal reminder sent with birthday card, 
followed by one telephone reminder. 
 
Not known at this address – use maternal 
grandparent contact details or ONS. 
Non-respondents at two years: One postal 
followed by one telephone reminder. 
 
 
 
 
 
 
Christmas cards sent, 
as appropriate, to 
children born within trial 
Mailings to infants / parents 
Mailings to health professionals 
1 year : All infants sent 1st birthday card 
 
Non-respondents to questionnaire above: One 
postal reminder sent with birthday card, 
followed by one telephone reminder. 
 
Not known at this address – use maternal 
grandparent contact details or ONS. 
BMC Health Services Research 2007, 7:2 http://www.biomedcentral.com/1472-6963/7/2agreed quit date
ii) Remaining baseline data for online entry
The following data will be collected with above data and
the RM will also enter this on to the online database but
entering these variables will not be mandatory before
online randomisation is permitted.
NHS number (for ONS registration)
ethnic group
age left full time education
number of previous births beyond 24 weeks (valid range 0–
12)
time to first cigarette of day [29]
partner's smoking status
maternal height
maternal weight at booking appointment
saliva sample
iii) Baseline data stored on paper
These personal data will be recorded on paper to allow
data protection as the internet is not a secure transport
medium.
Participant name and contact details (including landline/
mobile telephone number & postcode)
previous surname(s) – for ONS registration
Participant's general practitioner and/or name of practice plus
practice address grandparents' contact details, including
phone numbers
b) One month after quit date
RM collects data from those who return. Postal question-
naires sent from NTCT to those who do not. The following
data are collected:
RM notes whether or not follow up occurs and the date of any
follow up. RM also inspects participants' supply of patches
to calculate the number used.
Smoked at all in the previous 24 hrs
Smoked since quit date (further details on outcomes form
1)
Exhaled CO reading
On how many days have patches been used?
On how many days (if any) have non-trial patches been used?
How many behavioural support sessions with NHS stop smok-
ing services used (telephone & face to face)?
Saliva sample for cotinine estimation taken
c) Upon admission for childbirth
The following data are recorded by the RM or delivery
suite staff:
Date of follow up/exhaled CO reading or saliva sample
Smoked at all in the 24 hrs prior to delivery
Smoked between quit date and delivery
One or both of, i) exhaled CO reading & ascertainment date
ii) saliva sample (for cotinine)
On how many days have patches been used?
On how many days (if any) have non-trial patches been used?
How many behavioural support sessions with NHS stop smok-
ing services used (telephone & face to face)?
i) These data obtained by RM from maternal or infant
medical records before discharge. For reasons of data pro-
tection some personal infant details are recorded on paper
rather than being transmitted over the internet to the trial
database:
maternal 
hypertension (>140/90) on 2 occasions (excluding labour)
miscarriage (between randomisation and 24 weeks)
labour onset (spontaneous, induced, no labour)
mode of delivery (SVD, instrumental, caesarean)
ante natal or post natal maternal hospital admission
infant
baby initials
D.O.BPage 10 of 15
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Baby NHS number
Prompt for RM to confirm full name and address and contact
details of baby and to record these on paper (see below)
Prompt for RM to make a new record of contact details if these
have differed from previous (i.e. maternal) ones
baby hospital number
birth weight
Number of births
if multiple birth, indicate number and birth order
live or stillbirth?
cord ph < 7.0
Apgar <7 at 5 min
Gestational age at birth – to be calculated within database
from gestation at recruitment
These infant personal details will be recorded on paper
only:
baby name
baby address (inc postcode)
ii) These data obtained by research midwife from infant
medical records after discharge:
If live birth? live on leaving hospital
ventilation > 24 hrs
necrotising enterocolitis
neonatal convulsions
admitted to special care
intraventricular haemorrhage (4 categories)
congenital abnormality present (y/n). If y then free text to
describe this.
d) Six months after delivery
The following data will be requested by postal question-
naire, dispatched from the trial office:
Smoking status
Length of maternal inpatient stay for delivery of > 24 hours
duration (if any)
Any infant neonatal admission to special care
Length of any infant inpatient stay on special care
Maternal use of NRT/NHS stop smoking services since child-
birth,
EQ5D questionnaire [20]
e) At 1 year after delivery
The following data will be requested: smoking status, respi-
ratory symptoms and infant hospital admissions for respiratory
illness and other causes
e) At 2 years after delivery
The following data will be requested:
Parent questionnaire – Smoking status, infant behaviour,
development, respiratory symptoms and hospital admissions.
Health professional questionnaire – Child's disability
Interventions
Details of NRT patches are given earlier in this document
and details of behavioural support follow. The first behav-
ioural support session will be provided at recruitment by
a research midwife who has been trained in smoking ces-
sation methods in accordance with national standards
[30] and who has dedicated time for this task. Models of
behavioural support that are effective in pregnancy vary
greatly[7] and in non-pregnant subjects, behavioural sup-
port following very different psychological models are all
equally effective [31]. We will, therefore, standardise the
first support session to include information on:
i) the harmful effects of smoking in pregnancy
ii) the role of nicotine addiction in sustaining smoking
iii) how to use NRT (including safety concerns)
iv) coping with withdrawal symptoms.
Support will be specific to the needs of pregnant women
and may involve:
i) enlisting partner support
ii) a partner quit attemptPage 11 of 15
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ing cessation services
Study midwives will use brief cognitive – behavioural
counselling, combining components from effective coun-
selling strategies that are effective [31], such as:
i) providing structure to quit attempts
ii) agreeing a "contract" for any attempt
Counselling will be delivered in a manner that is consist-
ent with routine clinical practice, using a format similar to
that which has been effectively applied within routine
ante natal care in the US [32]. A quit date which is within
2 weeks will be agreed and participants will be instructed
to start using patches on this date.
Local NHS stop smoking services will provide up to 5 sub-
sequent behavioural support sessions. These follow up ses-
sions will reinforce women's reasons for quitting and
strategies for success. A standardised approach to follow
up support sessions is important and NHS stop smoking
service staff will be orientated towards this.
General statistical analysis plan
a) Primary outcome measure
The proportion of women who report prolonged and total
abstinence from smoking immediately before child birth
will be compared between treatment groups by Chi-
squared test, on an intention to treat basis (all those ran-
domised) with smokers lost to follow up considered to
have continued smoking. For this analysis, we will assume
that women in each group use their allocated treatments
as directed and no randomised participants will be
excluded from analyses. Baseline data on smoking behav-
iour and demographic information will be compared
between groups, and adjustment made for any differ-
ences, using logistic regression.
b) Child behaviour and development scores at 2 years
We will compare in children born to women in the con-
trol and intervention groups, using t-test (via log transfor-
mation) or the Mann-Whitney U statistic. Again this will
be done on an intention to treat basis. A small number of
children will be born as multiple births (e.g. twins) and
data for these cases will be clustered rather than independ-
ent. Robust standard errors, or a similar appropriate statis-
tical method will be used in analysis of child data to allow
for this.
There will be two analyses. The first will be conducted
upon data obtained around delivery. The second will be
conducted at 2 years after delivery, using data obtained
between delivery and this time point. Data collected for
secondary outcomes will not be analysed until the trial
has ended with respect to the primary outcome measure.
c) Other outcomes
i) Fetal birth outcomes and ii) Maternal birth outcomes will
also be compared on an intention to treat basis between
the 2 groups in the first analysis at delivery (as a & b above)
As these outcomes relate to the safety of NRT in pregnancy
we will also conduct an analysis of these outcomes com-
paring participants in each group who report using any
patches with those in each group who report using none.
d) Sub group analyses
These will be conducted to investigate the relationship
between i) baseline cotinine levels and cessation and ii)
maternal educational level (proxy for socio-economic sta-
tus) and cessation. We will model the relationship
between smoking cessation, pre-treatment plasma coti-
nine levels and treatment group in a logistic regression, to
establish whether there is effect modification by pre-treat-
ment plasma cotinine and whether efficacy at given levels
of plasma cotinine varies. The model will also establish
whether or not smoking cessation is constant across all
levels of pre-treatment plasma cotinine in the NRT group,
or reduces with increasing pre-treatment plasma cotinine,
which could be indicative of inadequate replacement of
nicotine. We will use similar methods to investigate ii)
above.
Health economic analysis plan
Economic analysis will be undertaken to investigate short
term and longer term potential cost-effectiveness of NRT
in pregnancy. The cost-effectiveness of NRT use by the
general population has been established [33] and a small
number of studies have investigated the potential cost sav-
ing of smoking cessation interventions in pregnancy. [34],
but few have used empirical data on costs of interven-
tions. Analyses for this study will be primarily undertaken
from an NHS perspective. Uptake of behavioural support
and NRT will be monitored and costs of both estimated
with both locally-specific and national average values. The
differential consequences in terms of length of maternal
stay and post natal delivery to special care between the
two arms of the trial will be used with the estimated costs
of delivering interventions with and without NRT patches
and differential smoking cessation rates to estimate the
incremental cost-effectiveness ratio. Sensitivity analyses
exploring assumptions made in estimating the control
state (no NRT) will be undertaken. The primary health
outcome will be maternal smoking cessation immediately
before delivery and differences in health status at 6
months (from EQ5D data) will be converted into QALYs
to allow cost-utility modelling. Additionally, a range of
modelling techniques will be used to estimate longer-Page 12 of 15
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logical and economic models will be used to estimate life-
time gains in QALYs from smoking cessation and savings
in health care expenditures [33,35]. A full literature review
will be undertaken to explore the potential for providing
monetary estimates of the long term impacts on the child
of their differential birth outcomes.
Safety
To minimise the likelihood of women or infants being
harmed by unexpected effect(s) of nicotine that could not
predicted from previous research, the Data Monitoring &
Ethics Committee will have access to birth outcome data.
These data will be available for the DMEC to analyse as is
considered appropriate to investigate whether or not sig-
nificant or clinically-important differences arise between
study groups (e.g. in birth weight).
Safety reporting
The following will be considered adverse events (AEs):
Withdrawal from patch treatment due to i) skin reaction
or ii) other symptom(s) which are potentially caused by
NRT (listed in section 4.10 BNF)
AEs will be reported in an annual safety report to the
MHRA, REC and Sponsor.
The following will be considered Suspected Unexpected
Severe Adverse Reactions (SUSARs):
Baby: fetal death, still birth, neonatal and post-neonatal
death, congenital abnormality, special care admission
(excluding transitional care admission)*
Maternal: eclampsia, maternal death, some hospital
admissions* (see below)
Birth outcome: placental abruption, premature birth (ear-
lier than 32 weeks)*, low birth weight (< 2,500 g)
The following hospital admissions are not SUSARS:
admission for delivery, uncomplicated false labour,
unconfirmed fetal compromise (i.e. baby well), vaginal
bleeding of no serious cause and infant hospital admis-
sions after the neonatal period
Any other serious unexpected event.
All SUSARs except those marked with an asterisk* are con-
sidered life threatening.
Life threatening or fatal SUSARs (no asterisk) will be
reported to the MHRA and REC within 7 days (follow up
report within 15 days) and also to relevant NHS trust R&D
office according to local policies.
Non life threatening SUSARs (asterisk) will be reported to
the MHRA and REC within 15 days and also to R&D
offices, as appropriate.
SUSARs will also be reported to the DMEC chair along
with the treatment allocation group of the trial subject
and a cumulative count of SAE and SUSAR frequency in
each trial arm.
Trial steering committee
Data monitoring and ethics committee
Funding
The research costs of SNAP are funded by the NHS Health
Technology Assessment Programme and the NHS Support
Costs have been met from NHS R&D funds.
Discussion
Recruitment to the SNAP trial will start in 2007 and at the
conclusion of the trial, it should produce valuable infor-
Table 2: 
Professor Janet Peacock (Chair) Professor of Health Statistics, Brunel University
Professor Khalid Khan Professor of Obstetrics, Gynaecology and Clinical Epidemiology, University of Birmingham
Professor David Field Professor of Neonatal Medicine, University of Leicester
Table 1: 
Mr Peter Brocklehurst (Chair) Director, National Perinatal Epidemiology Unit, University of Oxford
Professor Peter Hajek Professor of Clinical Psychology, Tobacco Dependence Research Centre, Barts and The London, Queen Mary's 
School of Medicine and Dentistry
Dr Carol Coupland Senior Lecturer in Medical Statistics, Division of Primary Care, University of Nottingham
Mrs Sue Maguire Lay member
Dr Michael Murphy Director, Childhood Cancer Research Group, University of OxfordPage 13 of 15
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nancy.
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